Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. https://doi.org/10.3322/caac.21654.
Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218–30. https://doi.org/10.1056/NEJMoa2002788.
Article CAS PubMed Google Scholar
von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–8.
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312–22. https://doi.org/10.1016/S1470-2045(17)30065-7.
Article CAS PubMed Google Scholar
Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019;30:970–6. https://doi.org/10.1093/annonc/mdz127.
Article CAS PubMed PubMed Central Google Scholar
Apolo AB, Ellerton JA, Infante JR, Agrawal M, Gordon MS, Aljumaily R, et al. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer. 2020;8: e001246. https://doi.org/10.1136/jitc-2020-001246.
Article PubMed PubMed Central Google Scholar
Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fléchon A, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39:2474–85. https://doi.org/10.1200/JCO.20.03489.
Article CAS PubMed PubMed Central Google Scholar
Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee J-L, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125–35. https://doi.org/10.1056/NEJMoa2035807.
Article CAS PubMed PubMed Central Google Scholar
Yu EY, Petrylak DP, O’Donnell PH, Lee J-L, van der Heijden MS, Loriot Y, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22:872–82. https://doi.org/10.1016/S1470-2045(21)00094-2.
Article CAS PubMed Google Scholar
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389(21):1961–71.
Article CAS PubMed Google Scholar
van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389:1778–89. https://doi.org/10.1056/NEJMoa2309863.
Powles TB, Perez Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. LBA6 EV-302/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann Oncol. 2023;34(Suppl 2):S1340. https://doi.org/10.1016/j.annonc.2023.10.106.
Gan K, Gao Y, Liu K, Xu B, Qin W. The clinical significance and prognostic value of HER2 expression in bladder cancer: a meta-analysis and a bioinformatic analysis. Front Oncol. 2021;11: 653491. https://doi.org/10.3389/fonc.2021.653491.
Article CAS PubMed PubMed Central Google Scholar
Grivas PD, Day M, Hussain M. Urothelial carcinomas: a focus on human epidermal receptors signaling. Am J Transl Res. 2011;3:362–73.
CAS PubMed PubMed Central Google Scholar
Koshkin VS, O’Donnell P, Yu EY, Grivas P. Systematic review: targeting HER2 in Bladder Cancer. Bladder Cancer. 2019;5:1–12. https://doi.org/10.3233/BLC-180196.
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle invasive bladder cancer. Cell. 2017;171:540-556.e25. https://doi.org/10.1016/j.cell.2017.09.007.
Article CAS PubMed PubMed Central Google Scholar
Ross JS, Wang K, Khaira D, Ali SM, Fisher HAG, Mian B, et al. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer. 2016;122:702–11. https://doi.org/10.1002/cncr.29826.
Article CAS PubMed Google Scholar
Ross JS, Wang K, Gay LM, Al-Rohil RN, Nazeer T, Sheehan CE, et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res. 2014;20:68–75. https://doi.org/10.1158/1078-0432.CCR-13-1992.
Article CAS PubMed Google Scholar
Galsky MD, Del Conte G, Foti S, Yu EY, Machiels J-PH, Doger B, et al. Primary analysis from DS8201-A-U105: a phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC). J Clin Oncol. 2022;40:438–438. https://doi.org/10.1200/JCO.2022.40.6_suppl.438.
Choudhury NJ, Campanile A, Antic T, Yap KL, Fitzpatrick CA, Wade JL, et al. Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. J Clin Oncol. 2016;34:2165–71. https://doi.org/10.1200/JCO.2015.66.3047.
Article CAS PubMed PubMed Central Google Scholar
Bryce AH, Kurzrock R, Meric-Bernstam F, Hurwitz H, Hainsworth JD, Spigel DR, et al. Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): preliminary data from MyPathway. J Clin Oncol. 2017;35(Suppl 6):348–348. https://doi.org/10.1200/JCO.2017.35.6_suppl.348.
Connolly R, Wang V, Hyman D, Grivas P, Mitchell E, Wright J, et al. 553P activity of trastuzumab and pertuzumab (HP) in patients with non-breast/gastroesophageal HER2-amplified tumours: results of the NCI-MATCH trial (EAY131) subprotocol. Ann Oncol. 2020;31(Suppl 4):S479–80. https://doi.org/10.1016/j.annonc.2020.08.667.
Powles T, Yu EY, Iyer G, Campbell MT, Loriot Y, De Santis M, et al. Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001). J Clin Oncol. 2023;41(Suppl 6):TPS594. https://doi.org/10.1200/JCO.2023.41.6_suppl.TPS594
RemeGen Co., Ltd. A study of RC48-ADC combined with toripalimab for first-line treatment of urothelial carcinoma. ClinicalTrials.gov identifier: NCT05302284. Updated December 18, 2023. Accessed 20 Dece 2023. https://clinicaltrials.gov/study/NCT05302284
Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol. 2010;21:815–9. https://doi.org/10.1093/annonc/mdp488.
Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol. 2011;60:350–7. https://doi.org/10.1016/j.eururo.2011.05.035.
Article CAS PubMed Google Scholar
Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3:224–37. https://doi.org/10.1158/2159-8290.CD-12-0349.
Article CAS PubMed Google Scholar
Mishra R, Hanker AB, Garrett JT. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget. 2017;8:114371–92. https://doi.org/10.18632/oncotarget.22825.
Article PubMed PubMed Central Google Scholar
Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, et al. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015;4:844–52. https://doi.org/10.1002/cam4.432.
Article CAS PubMed PubMed Central Google Scholar
Tschui J, Vassella E, Bandi N, Baumgartner U, Genitsch V, Rotzer D, et al. Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer. Virchows Arch Int J Pathol. 2015;466:703–10. https://doi.org/10.1007/s00428-015-1729-4.
Schneider SA, Sukov WR, Frank I, Boorjian SA, Costello BA, Tarrell RF, et al. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod Pathol. 2014;27:758–64. https://doi.org/10.1038/modpathol.2013.201.
Article CAS PubMed Google Scholar
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, et al. Ado-Trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36:2532–7. https://doi.org/10.1200/JCO.2018.77.9777.
Article CAS PubMed PubMed Central Google Scholar
de Martino M, Zhuang D, Klatte T, Rieken M, Rouprêt M, Xylinas E, et al. Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. Cancer Biol Ther. 2014;15:1239–47. https://doi.org/10.4161/cbt.29687.
Article CAS PubMed PubMed Central Google Scholar
Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023–31. https://doi.org/10.1038/nbt.2696.
留言 (0)